David A. Siegel Eq Rx, Inc. Transaction History

Two Sigma Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.66 - $2.31 $57,270 - $79,695	34,500 Added 102.07%	68,300 $151,000
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $15,456 - $18,816	9,600 Added 39.67%	33,800 $62,000
Q1 2023 May 15, 2023	BUY	$1.8 - $2.83 $43,560 - $68,486	24,200 New	24,200 $46,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.